Imclone Presents Preclinical Data on Bladder Carcinoma Therapeutic at American Association for Cancer Research Meeting.NEW YORK--(BW HealthWire)--April 14, 1997-- Shown To Inhibit Tumor Growth in Orthotopic Model ImClone Systems Incorporated (Nasdaq: IMCL IMCL International Making Cities Livable IMCL Inter Marine Container Lines IMCL International Management Consultants Ltd. IMCL Indraprastha Medical Corp Ltd (India) IMCL Imperial Majesty Cruise Line ) today announced promising results of a preclinical study of the Company's lead cancer therapeutic, C225, an epidermal growth factor receptor This article is about a cell suface receptor. For estimated measure of kidney function (eGFR), see Glomerular filtration rate. The epidermal growth factor receptor (EGFr) antagonist at the 88th annual meeting of the American Association for Cancer Research Wikipedia is not the place for advertisement or self-advertising. The American Association for Cancer Research (AACR) is an organization based in Philadelphia, Pennsylvania, that focuses on all aspects of cancer research including basic, clinical and translational in San Diego, CA. As presented by Robert Radinsky, Ph.D., Assistant Professor, Department of Cell Biology, MD Anderson Cancer Center in Houston, Texas, treatment with C225 in human bladder carcinoma cells growing orthotopically in mice resulted in a significant inhibition of tumor growth (p<0.05) compared with controls. The orthotopic approach utilized in this study is a cancer model that implants human tumor cells into the tissue of origin in the mouse, thus making the model a more realistic indicator of tumor progression. "These research findings provide additional proof of principle in a compelling orthotopic model system of C225 in targeting the EGF EGF abbr. epidermal growth factor receptor," said Harlan W. Waksal, M.D., Executive Vice President and Chief Operating Officer Chief Operating Officer (COO) The officer of a firm responsible for day-to-day management, usually the president or an executive vice-president. of ImClone Systems. "We believe this further supports the mechanism of C225's anti-tumor activity." C225 blocks the EGF receptor, which has been shown to be over-expressed on the cells of approximately one-third of all cancers. Antibodies directed against EGFr may inhibit the uncontrolled cancer cell growth that has been shown to be associated with the receptor's activity. In 1996, ImClone initiated three Phase Ib/IIa clinical trials of C225 in combination with various chemotherapeutic agents. Patients with advanced head, neck and lung carcinomas were treated with the chemotherapeutic agent chemotherapeutic agent An agent used to treat CA, administered in 'regimens'-one or more 'cycles' that combine 3 or more agents over wks; CAs are toxic to any cell with a high rate of proliferation–the CA itself, the GI tract–causing N&V, Cisplatin cisplatin /cis·plat·in/ (sis´plat-in) DDP; a platinum coordination complex capable of producing inter- and intrastrand DNA crosslinks; used as an antineoplastic. cis·plat·in n. . Additionally, patients suffering from advanced prostate carcinoma are being treated with C225 in conjunction with Adriamycin. Patients with breast cancer are currently being treated with C225 in combination with Taxol. ImClone Systems Incorporated, headquartered in New York New York, state, United States New York, Middle Atlantic state of the United States. It is bordered by Vermont, Massachusetts, Connecticut, and the Atlantic Ocean (E), New Jersey and Pennsylvania (S), Lakes Erie and Ontario and the Canadian province of , is a biopharmaceutical company developing novel therapeutic products including interventional therapeutics, cancer vaccines Cancer vaccines A treatment that uses the patient's immune system to attack cancer cells. Mentioned in: Pancreatic Cancer, Exocrine and blood cell growth factors for the treatment of cancer and cancer-related disorders. Except for the historical information contained herein, the matters discussed in this news release include forward-looking statements. Actual results may differ materially from those predicted in such forward-looking statements due to the risks and uncertainties inherent in the Company's business, including, without limitation, risks and uncertainties in obtaining and maintaining regulatory approval, market acceptance of and continuing demand for the Company's products, the impact of competitive products and pricing, and the Company's ability to obtain additional financing to support its operations. CONTACT: Andrea Rabney Director of Corporate Development and Investor Relations ImClone Systems Incorporated (212) 645-1405 or Karen Bergman (Media inquiries) Scott Lerman (Media inquiries) Reagan Codner (Investor inquiries) Burns McClellan, Inc. (212) 505-1919 |
|
||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion